Trials / Terminated
TerminatedNCT04473651
Safety and Tolerability of Lu AG06479 in Healthy Young Men
Interventional, Randomized, Double-blind, Placebo-controlled, Sequential-group, Single-ascending Oral Dose Study Investigating the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Properties of Lu AG06479 and Open-label Cross-over Study to Investigate Intra-subject Variability and Effect of Food in Healthy Young Men
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the safety and tolerability of Lu AG06479 and what the body does to Lu AG06479 after swallowing single doses of the drug.
Detailed description
Part A: randomized, sequential Part B: open-label, cross-over
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lu AG06479 | capsules, orally (Part A and B) |
| DRUG | Placebos | Placebo - capsules, orally (Part A only) |
Timeline
- Start date
- 2020-07-09
- Primary completion
- 2021-11-10
- Completion
- 2021-11-10
- First posted
- 2020-07-16
- Last updated
- 2021-12-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04473651. Inclusion in this directory is not an endorsement.